Verastem Inc. (VSTM)
NASDAQ: VSTM
· Real-Time Price · USD
8.70
-0.29 (-3.23%)
At close: Oct 03, 2025, 3:59 PM
8.73
0.34%
After-hours: Oct 03, 2025, 07:13 PM EDT
-3.23% (1D)
| Bid | 8.7 |
| Market Cap | 535.44M |
| Revenue (ttm) | -7.84M |
| Net Income (ttm) | -166.56M |
| EPS (ttm) | -3.49 |
| PE Ratio (ttm) | -2.49 |
| Forward PE | -4.66 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.95 |
| Volume | 1,506,443 |
| Avg. Volume (20D) | 2,429,055 |
| Open | 9.04 |
| Previous Close | 8.99 |
| Day's Range | 8.68 - 9.26 |
| 52-Week Range | 2.54 - 11.25 |
| Beta | 0.89 |
| Ex-Dividend Date | n/a |
About VSTM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VSTM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VSTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsVerastem Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+19.93%
Verastem shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago
-19.95%
Verastem shares are trading lower. The company provided updated data for the dose escalation part of its Phase 1/2 trial of GFH375.
2 months ago · businesswire.com
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
